Denali Therapeutics price target lowered to $28 from $30 at BofA
BofA lowered the firm’s price target on Denali Therapeutics (DNLI) to $28 from $30 and keeps a Buy rating on the shares. The firm updated for ...
Morgan Stanley Begins Coverage on Denali Therapeutics (NASDAQ:DNLI)
Morgan Stanley assumed coverage on shares of Denali Therapeutics (NASDAQ:DNLI – Free Report) in a report published on Friday, ...
Proficio Capital Partners LLC Acquires New Shares in Denali Therapeutics Inc. (NASDAQ:DNLI)
Proficio Capital Partners LLC acquired a new stake in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) during the 4th quarter, Holdings Channel reports. The fund acquired 25,210 shares of the ...